Replies to post #122019 on Anavex Life Sciences Corp (AVXL)

[OFP]

CTAD Boston - November 1-4, 2017

LBP33: Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease

Finally some actual data! I was not able to search the program...anything on a 104 week data update?...that update was REMOVED from the 2017 list of catalysts. Not a good sign IMO. Also removed from list of catalysts was reference to possible in-licensing. As before, the only completed items in the 2017 list are events that occurred in 2016!

Multiple Sclerosis as part of the pipeline chart has been DELETED. What's the positive spin on that?